Project Grant 2030305

This $2,178,000 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a "tunable nanophage platform" for rapid vaccine design and screening against emerging infectious disease threats. The key objectives are to engineer "second generation" nanophage particles that can display the spike receptor binding domains of SARS-CoV-2 and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a self-administered microneedle patch for the long-acting release of antiretroviral agents. The primary goals are to: 1) formulate and optimize the extended release of the antiretroviral drug islatravir (EFDA) from biodegradable microneedle patches for at least one month, and 2) determine the in vivo...

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

This National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I grant, awarded under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $274,991 to Duravax Inc. to develop thermostable formulations of mRNA vaccines and therapeutics. The project aims to overcome the cold-chain limitations of current mRNA products by demonstrating the feasibility of storing mRNA APIs and mRNA-lipid nanoparticles at room temperature for extended periods. If...

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $615,370 Project Grant (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a featherweight, pulse-driven micropump for continuous transdermal drug delivery. The project aims to characterize the infusion rate capabilities of the prototype micropump, optimize its design to deliver a...

This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...

Tempo Therapeutics, Inc. received a $1 million cooperative agreement from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a multivalent vaccine platform to provide durable immunity against multiple coronaviruses. Specifically, the funding will support Tempo Therapeutics' efforts to determine the optimal dose, assess durability of immune response, evaluate protective immunity against SARS-CoV-2 variants, and develop a...

Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022. The NSF Technology, Innovation, and...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research by HDT Bio Corp to study the immunological mechanisms of muscle-localizing self-replicating RNA (RepRNA) vaccines. The $3,878,480 award aims to characterize the role of skeletal muscle dendritic cells in vaccine immunogenicity, investigate how type I interferon signaling limits transgene expression...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $668,569 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Schepens Eye Research Institute, Inc. The purpose of this 5-year grant is to characterize and optimize a novel genetic vaccine platform called PARVAX for improved clinical acceptance and pandemic preparedness. The key goals are to: 1) investigate the mechanism behind the potency and durability of PARVAX, 2) use...